Information Provided By: 
Fly News Breaks for September 28, 2015
ALNY
Sep 28, 2015 | 11:14 EDT
Piper Jaffray analyst Edward Tenthoff said he believes Alnylam's updated data from the Phase II Open Label Extension study of patisiran has a positive read through to the company's ongoing Phase III APOLLO trial. The analyst, who thinks Alnylam still has a number of potential catalysts in the coming months, reiterates an Overweight rating and $184 price target on the stock, which is down $3.25 to $80.47 in morning trading.
News For ALNY From the Last 2 Days
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
